Brucke Financial Inc. bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 8,804 shares of the company's stock, valued at approximately $623,000.
A number of other institutional investors have also modified their holdings of the company. Capital International Investors boosted its holdings in shares of AstraZeneca by 1.9% in the 4th quarter. Capital International Investors now owns 37,507,159 shares of the company's stock valued at $2,457,706,000 after buying an additional 686,008 shares in the last quarter. Bank of America Corp DE raised its position in shares of AstraZeneca by 189.3% in the 4th quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock valued at $1,574,247,000 after purchasing an additional 15,722,197 shares during the last quarter. Franklin Resources Inc. raised its position in shares of AstraZeneca by 1.9% in the 4th quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock valued at $1,276,367,000 after purchasing an additional 357,894 shares during the last quarter. Jennison Associates LLC raised its position in shares of AstraZeneca by 3.1% in the 4th quarter. Jennison Associates LLC now owns 15,430,963 shares of the company's stock valued at $1,011,037,000 after purchasing an additional 466,416 shares during the last quarter. Finally, Sanders Capital LLC raised its position in shares of AstraZeneca by 1.4% in the 4th quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock valued at $995,032,000 after purchasing an additional 212,301 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.
AstraZeneca Stock Performance
AZN traded up $1.95 during trading on Friday, reaching $72.82. 8,033,731 shares of the company's stock were exchanged, compared to its average volume of 5,194,017. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. The stock has a market capitalization of $225.83 billion, a P/E ratio of 32.22, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The company's fifty day simple moving average is $69.38 and its 200-day simple moving average is $69.67.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The company had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same period last year, the firm posted $2.06 EPS. AstraZeneca's revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts recently commented on AZN shares. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective for the company. Finally, Morgan Stanley started coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They issued an "overweight" rating for the company. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $85.00.
Check Out Our Latest Stock Report on AstraZeneca
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
